Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Baricitinib Patent Expiration

Baricitinib is Used for treating severe alopecia areata, COVID-19 in hospitalized adults requiring supplemental oxygen, ventilation, or ECMO, and rheumatoid arthritis. It was first introduced by Eli Lilly And Co in its drug Olumiant on May 31, 2018.


Baricitinib Patents

Given below is the list of patents protecting Baricitinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Olumiant US11045474 Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections Nov 30, 2032 Eli Lilly And Co
Olumiant US11806555 Methods for treating hair loss disorders Nov 02, 2031 Eli Lilly And Co
Olumiant US8158616 Azetidine and cyclobutane derivatives as JAK inhibitors May 31, 2032 Eli Lilly And Co
Olumiant US8420629 Azetidine and cyclobutane derivatives as JAK inhibitors Mar 10, 2029 Eli Lilly And Co
Olumiant US9089574 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections Nov 30, 2032 Eli Lilly And Co
Olumiant US9737469 Methods for treating hair loss disorders Nov 02, 2031 Eli Lilly And Co


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳